Amanda Henderson, MD
Ophthalmology · Baltimore, MDNPI 1194011106
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Amgen accounts for 93.7% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $6,493, more than ten times the $20 reported in 2019. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 20 payments — averaging $961.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$18K
- Catalyst Pharmaceuticals, Inc.$1K
- Bsn Medical Inc$20
Across 57 payments — averaging $1123.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$64K
What the payments were for
- Consulting fees$10,41454%
- Speaking & faculty fees$8,44044%
- Food & beverage$3802%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 18 | $18,014 |
| Catalyst Pharmaceuticals, Inc. | 1 | $1,200 |
| Bsn Medical Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,234 in reported general payments places this provider in the 90th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Travoprost | 13 | $1,729 |
| Acetazolamide ErAcetazolamide | 13 | $1,276 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Baltimore
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Neil BresslerBaltimore$265K
- Adrienne ScottBaltimore$170K
- Jennifer ThorneBaltimore$128K
- Earl CravenBaltimore$120K
- Peter CampochiaroBaltimore$103K
- Gail SchwartzBaltimore$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.